2025年泰康医疗健康股票发起下跌13% 牛市跌幅两位数

Group 1 - The core viewpoint of the news is that the Taikang Medical Health Fund has experienced significant declines in its stock performance for both Class C and Class A shares, with decreases of 13.45% and 13.02% respectively in 2025 [1][2] - The top ten holdings of the fund as of the third quarter of 2025 include companies such as Jingtai Holdings, Kanglong Chemical, Fangzhou Jianke, Sanofi Pharmaceutical, Zhaoyan New Drug, Jiuan Medical, Yirui Technology, Lingrui Pharmaceutical, Baipusais, and Bid Medical [1] - The fund manager, Fu Hongzhe, has a background as a senior researcher at China Europe Fund Management Co., Ltd. and has been with Taikang since July 2019, becoming the fund manager on March 8, 2022 [1]